Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives $23.00 Average PT from Brokerages

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have received an average rating of “Reduce” from the eight research firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $23.00.

A number of analysts have recently issued reports on the stock. Citigroup raised their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target for the company.

Integra LifeSciences Price Performance

Shares of IART opened at $23.60 on Thursday. The business’s 50-day moving average is $23.74 and its two-hundred day moving average is $21.84. The company has a market capitalization of $1.82 billion, a P/E ratio of -262.19, a P/E/G ratio of 0.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $44.69.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. The firm had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company posted $0.89 EPS. Research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Insider Activity at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.10% of the stock is owned by insiders.

Institutional Trading of Integra LifeSciences

Several institutional investors have recently added to or reduced their stakes in IART. Quadrant Capital Group LLC grew its stake in shares of Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 1,371 shares in the last quarter. Sterling Capital Management LLC grew its stake in shares of Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock worth $49,000 after acquiring an additional 1,931 shares in the last quarter. KBC Group NV grew its stake in shares of Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after acquiring an additional 1,120 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after acquiring an additional 2,800 shares in the last quarter. Finally, Covestor Ltd grew its stake in shares of Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock worth $123,000 after acquiring an additional 2,071 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.